Mabpharm (HKG:2181) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥258.2m (up 196% from FY 2023).
- Net loss: CN¥127.9m (loss narrowed by 39% from FY 2023).
- CN¥0.031 loss per share (improved from CN¥0.051 loss in FY 2023).
2181 Products In Clinical Trials
- Phase I: 3.
- Phase III: 7.
2181 Post-Clinical Trial Products
- Approved (during full year): 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
In the last 12 months, the only revenue segment was Pharmaceuticals contributing CN¥258.2m. The largest operating expense was Sales & Marketing costs, amounting to CN¥151.6m (44% of total expenses). Explore how 2181's revenue and expenses shape its earnings.
Mabpharm shares are down 7.1% from a week ago.
Risk Analysis
Be aware that Mabpharm is showing 2 warning signs in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.